Celularity Inc. develops regenerative and cellular medicine products based on placental-derived technologies. Its programs include allogeneic cell therapies such as natural killer cells, engineered T cells including CAR-T cells, mesenchymal-like stromal cells, and biologic products including Biovance, Biovance 3L, Interfyl, and CentaFlex.
Recurring news for CELUW covers clinical and regulatory disclosures for wound care, diabetic foot ulcers, ophthalmic biologics, and other degenerative-disease applications; product licensing and manufacturing arrangements; operating and financial results; governance updates; and capital-structure actions, including financing arrangements and monetization of New Jersey tax assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.